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IntegrinCCN4 is a cysteine-rich protein that belongs to the Cyr61, CTGF, Nov family of matricellular proteins. Here, we
investigated the intracellular signaling pathways involved in CCN4-induced vascular cell adhesion
molecule-1 expression in human osteoarthritis synovial ﬁbroblasts. Stimulation of OASFs with CCN4 induced
VCAM-1 expression. CCN4-induced VCAM-1 expression was attenuated by αvβ5 or α6β1 integrin antibody,
Syk inhibitor, PKCδ inhibitor (rottlerin), JNK inhibitor (SP600125), and AP-1 inhibitors (curcumin and
tanshinone). Stimulation of cells with CCN4 increased Syk, PKCδ, and JNK activation. Treatment of OASFs
with CCN4 also increased c-Jun phosphorylation, AP-1-luciferase activity, and c-Jun binding to the AP-1 ele-
ment in the VCAM-1 promoter. Moreover, up-regulation of VCAM-1 increased the adhesion of monocytes to
OASF monolayers, and this adhesion was attenuated by transfection with a VCAM-1 siRNA. Our results sug-
gest that CCN4 increases VCAM-1 expression in human OASFs via the Syk, PKCδ, JNK, c-Jun, and AP-1 signal-
ing pathways. The CCN4-induced VCAM-1 expression promoted monocyte adhesion to human OASFs.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Osteoarthritis (OA) is a chronic joint disorder characterized by
slow progressive degeneration of articular cartilage, subchondral
bone alteration, and variable secondary synovial inﬂammation. In re-
sponse to macrophage-derived proinﬂammatory cytokines such as
interleukin (IL)-1β and tumor necrosis factor-α (TNF-α), OA synovial
ﬁbroblasts (OASFs) produce chemokines that promote inﬂammation,
neovascularization, and cartilage degradation via activation of matrix-
degrading enzymes such as matrix metalloproteinases (MMPs) [1,2].
Although the pathogenesis of the disease remains elusive, accumulat-
ing evidence indicates that mononuclear cell migration plays an impor-
tant role in the perpetuation of inﬂammation in the synovium [3,4].
Mononuclear cell adhesion and inﬁltration into inﬂammatory sites
are regulated by adhesion molecules, such as vascular cell adhesion
molecule-1 (VCAM-1) [5,6].ogy, School of Medicine, China
aiwan. Tel.: +886 4 22052121
g).
l rights reserved.Cell adhesion molecules are transmembrane glycoproteins that
mediate cell–cell and cell–extracellular matrix interactions. VCAM-1
emerged as a highly signiﬁcant predictor of the risk of OA [7,8].
VCAM-1 has been shown to be upregulated in the synovial lining of
OA patients by immunohistochemical staining, and in cultured
human OASFs by western blotting [7,8]. A reduction in the levels of
VCAM-1 in synovial ﬂuid may suppress the inﬂammatory response
in knee OA [9]. Therefore, VCAM-1 is involved in the process of mono-
nuclear cell inﬁltration into the synovium, leading to the initiation
and progression of the disease. However, the molecular mechanisms
by which cytokines induce VCAM-1 expression in human OASFs re-
main unclear.
CCN4 belongs to the CCN family of matricellular proteins, which also
includes cysteine-rich 61 (Cyr61/CCN1), connective tissue growth factor
(CTGF/CCN2), nephroblastoma overexpressed (NOV/CCN3), WISP-1/
CCN4, WISP-2/CCN5, and WISP-3/CCN6 (which is highly expressed in
skeletal tissues) [10]. CCN4 acts in an autocrine manner to accelerate
cell growth, induce morphological transformation, increase saturation
density, and promote tumorigenesis [11]. CCN4 also promotes osteo-
blastic differentiation [12]. A recent study showed that CCN4 expression
was increased in the synovium and cartilage of mice with experimental
OA [10]. Signiﬁcantly, recombinant CCN4 elicited the release of MMPs
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OA progression [10].
Although the roles of cytokines and adhesion molecules in poly-
morphonuclear cell adhesion to endothelial cells have been well
described, little is known about the mechanisms underlying the inter-
action between monocytes and human OASFs. Previous studies have
shown that CCN4 plays an important role in OA pathogenesis [10].
In the present study, we investigated the intracellular signaling path-
ways involved in CCN4-induced VCAM-1 expression in human OASFs.
The results show that CCN4 activates the integrin receptor and elicits
the activation of the Syk, PKCδ, JNK, and AP-1 signaling pathways,
leading to the upregulation of VCAM-1 expression. The increased
VCAM-1 expression correlated with enhanced adhesion of monocytes
to CCN4-stimulated OASFs.
2. Materials and methods
2.1. Materials
Protein A/G beads, anti-mouse and anti-rabbit IgG-conjugated
horseradish peroxidase, rabbit polyclonal antibodies speciﬁc for Syk,
PKCδ, JNK, p-JNK, ERK, p-ERK, p38, p-p38, c-Jun, p-c-Jun, and β-actin,
and siRNAs against Syk, PKCδ, and c-Jun were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal antibody
speciﬁc for Syk phosphorylated at Thr874 and PKCδ phosphorylated at
Tyr331 was purchased from Cell Signaling and Neuroscience (Danvers,
MA, USA). Mouse monoclonal antibodies speciﬁc for α5β1, αvβ3,
αvβ5, andα6β1 integrins were purchased from Chemicon (Temecula,
CA, USA). Syk inhibitor, rottlerin, GF109203X, Ro320432, SP600125,
SB203580, U0126, PD98059, curcumin, and tanshinonewere purchased
from Calbiochem (San Diego, CA, USA). Recombinant human CCN4
was purchased from R&D Systems (Minneapolis, MN, USA). All other
chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA).
2.2. Cell cultures
The study was approved by the local ethics committee, and in-
formed written consent was obtained from the subjects. Human
synovial ﬁbroblasts (SFs) were isolated by collagenase treatment of
synovial tissues obtained from knee replacement surgeries of 38 pa-
tients with OA and 18 samples of normal synovial tissues obtained
at arthroscopy from trauma/joint derangements. Synovial ﬂuid con-
centrations of CCN4 were measured with an enzyme-linked immu-
nosorbent assay (ELISA), according to the protocol provided by the
manufacturer (Human CCN4 ELISA kit; R&D Systems). OASFs were
isolated, cultured, and characterized as previously described [13,14].
Experiments were performed using cells from passages 3–6.
THP-1, a human leukemia cell line of monocyte/macrophage line-
age, was obtained from American Type Culture Collection (Manassas,
VA, USA) and grown in RPMI-1640 medium containing 10% fetal bo-
vine serum.
2.3. Quantitative real-time PCR
Total RNAwas extracted fromOASFs using a TRIzol kit (MDBio Inc.,
Taipei, Taiwan). The reverse transcription reaction was performed
using 2 μg of total RNA and oligo(dT) primer [15,16]. Quantitative
real-time PCR (qPCR) analysis was carried out using Taqman® one-
step PCR Master Mix (Applied Biosystems, Foster City, CA). cDNA tem-
plates (2 μl) were added to a 25-μl reaction along with sequence-
speciﬁc primers and Taqman® probes. All the target gene primers and
probes were commercially purchased (VCAM-1; ID, Hs01003370_m1).
β-actin (ID, Hs99999903_m1)was used as the internal control (Applied
Biosystems). The qPCR assays were carried out in triplicate on a
StepOnePlus sequence detection system. The cycling conditions com-
prised 10-min polymerase activation at 95 °C, followed by 40 cycles at95 °C for 15 s and 60 °C for 60 s. The threshold was set above the
non-template control background and within the linear phase of the
target gene ampliﬁcation to calculate the cycle number at which the
transcript was detected (denoted CT).
2.4. Western blot analysis
Cellular lysates were prepared as described previously [17,18].
Proteins were resolved on SDS-PAGE and transferred to immobilon
polyvinyldiﬂuoride (PVDF) membranes. The blots were blocked with
4% BSA for 1 h at room temperature and then probed with rabbit
anti-human antibodies against PKCδ, VCAM-1, or JNK (1:1000) for
1 h at room temperature. After three washes, the blots were subse-
quently incubated with donkey anti-rabbit peroxidase-conjugated sec-
ondary antibody (1:3000) for 1 h at room temperature. The blots were
visualized by enhanced chemiluminescence with Kodak X-OMAT LS
ﬁlm (Eastman Kodak, Rochester, NY). Quantitative data were obtained
using a computing densitometer and ImageQuant software (Supple-
mental data Fig. S1–6; Molecular Dynamics, Sunnyvale, CA, USA).
2.5. Transfection and reporter gene assay
Human synovial ﬁbroblasts were co-transfected with 0.8 μg AP-1-
luciferase plasmid, 0.4 μg β-galactosidase expression vector. Fibro-
blasts were grown to 80% conﬂuent in 12 well plates and were
transfected the following day with Lipofectamine 2000 (LF2000;
Invitrogen). DNA and LF2000 were premixed for 20 min and then ap-
plied to cells. After 24 h transfection, cells were then incubated with
the indicated agents. After further 24 h incubation, themedia were re-
moved, and cells were washed once with cold PBS. To prepare lysates,
100 μl reporter lysis buffer (Promega, Madison,WI)was added to each
well, and cells were scraped from dishes. The supernatant was collect-
ed after centrifugation at 13,000 rpm for 2 min. Aliquots of cell lysates
(20 μl) containing equal amounts of protein (20–30 μg) were placed
into wells of an opaque black 96-well microplate. An equal volume
of luciferase substrate was added to all samples, and luminescence
was measured in a microplate luminometer. The value of luciferase
activity was normalized to transfection efﬁciency monitored by the
co-transfected β-galactosidase expression vector.
2.6. Flow cytometry
Human synovial ﬁbroblasts were plated in six-well dishes. The
cells were then washed with PBS and detached with trypsin at 37 °C.
Cells were ﬁxed for 10 min in PBS containing 1% paraformaldehyde.
After being rinsed in PBS, the cells were incubated with mouse anti-
human antibody against VCAM-1 (1:100) for 1 h at 4 °C. Cells were
then washed again and incubated with ﬂuorescein isothiocyanate-
conjugated goat anti-mouse secondary IgG (1:100; Leinco Tec. Inc.,
St. Louis, MO, USA) for 45 min and analyzed by ﬂow cytometry using
FACS Calibur and CellQuest software (BD Biosciences).
2.7. Syk kinase activity assay
Syk activity was assessed using a Syk Kinase Activity Assay Kit
according to the manufacturer's instructions (Assay Designs, MI).
The Syk activity kit is based on a solid-phase ELISA that uses a speciﬁc
synthetic peptide as a substrate for Syk and a polyclonal antibody that
recognizes the phosphorylated form of the substrate.
2.8. Cell adhesion assay
THP-1 cells were labeled with BCECF-AM (10 μM) at 37 °C for 1 h
in RPMI-1640 medium and subsequently washed by centrifugation.
OASFs grown on glass coverslips were incubated with CCN4 for
6 h. Conﬂuent CCN4-treated OASFs were incubated with THP-1 cells
Fig. 1. CCN4 increases VCAM-1 expression through αvβ5/α6β1 integrin receptor. (A) Synovial ﬂuid was obtained from normal (n=10) or osteoarthritis patients (n=15) and
examined with ELISA for the expression of CCN4. (B) Human synovial ﬁbroblasts were cultured for 48 h, and media were collected to measure CCN4. (C–F) OASFs were incubated
with various concentrations of CCN4 for 24 h or with CCN4 (30 ng/ml) for 6, 12, or 24 h. The mRNA, cell surface, and protein expression of VCAM-1 were examined by qPCR, ﬂow
cytometry, and Western blotting. (G) OASFs were pretreated for 30 min with actinomycin D or cycloheximide followed by stimulation with CCN4 for 24 h, and VCAM-1 expression
was examined by qPCR. (H–J) OASFs were pretreated for 30 min with α5β1, αvβ3, αvβ5, or α6β1 integrin antibody (3 μg/ml) followed by stimulation with CCN4 for 24 h, and
VCAM-1 expression was examined by qPCR, ﬂow cytometry, and Western blotting. Results are expressed as the mean±S.E. *: pb0.05 as compared with basal level. #: pb0.05
as compared with CCN4-treated group.
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moved and gently washed with PBS. The number of adherent THP-1
cells was counted in four randomly chosen ﬁelds per well at 200×
high power using a ﬂuorescent microscope.Fig. 2. Syk is involved in CCN4-induced VCAM-1 expression. (A–C) OASFs were pretreated fo
stimulation with CCN4 for 24 h, and VCAM-1 expression was examined by qPCR, ﬂow cytom
intervals or pretreated with αvβ5 orα6β1mAb for 30 min before incubation with CCN4 for 1
Syk kinase assay kit. Results are expressed as the mean±S.E. *: pb0.05 as compared with b2.9. Chromatin immunoprecipitation assay
Chromatin immunoprecipitation analysis was performed as de-
scribed previously [19]. DNA was immunoprecipitated with an anti-r 30 min with Syk inhibitor (10 μM) or transfected with Syk siRNA for 24 h followed by
etry, and Western blotting. (D–G) OASFs were incubated with CCN4 for indicated time
5 min. The Syk phosphorylation and activity were determined byWestern blotting and
asal level. #: pb0.05 as compared with CCN4-treated group.
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phenol-chloroform. The puriﬁed DNA pellet was subjected to PCR,
and PCR products were resolved using 1.5% agarose gel electrophore-
sis and visualized with UV light. The forward and reverse primers
(5′-CGGTTAAATCTCACAGCCCA-3′ and5′-TTCTCTTACAAGAGAAAGGA-3′,
respectively) were speciﬁcally designed from the VCAM-1 promoter
region (−403 to−30) [20].
2.10. Statistical analysis
Data are expressed as mean±S.E. Statistical analyses were
performed using the Student's t-test. Statistical comparisons of more
than 2 groups were performed using one-way analysis of variance
(ANOVA)with Bonferroni's post-hoc test. In all cases, pb0.05was con-
sidered signiﬁcant.
3. Results
3.1. CCN4 induces VCAM-1 expression in human synovial ﬁbroblasts
CCN4 has been shown to play an important role in OA pathogene-
sis [21]. First, we examined human synovial tissues for the expression
of CCN4 using ELISA. CCN4 concentrations in synovial ﬂuid were sig-
niﬁcantly higher in patients with OA than in controls (Fig. 1A). TheFig. 3. PKCδ is involved in CCN4-induced VCAM-1 expression in synovial ﬁbroblasts. (A–C
Ro320432 (10 μM) or transfected with PKCδ siRNA for 24 h followed stimulated with CCN4
blotting. OASFs were incubated with CCN4 for indicated time intervals (D) or pretreated wi
15 min (E), and PKCδ phosphorylation was determined by Western blotting. Results are ex
pared with CCN4-treated group.medium from OASFs exhibited signiﬁcant levels of CCN4, which
were higher than that of the medium from normal SFs (Fig. 1B).
Next, we directly applied CCN4 to OASFs and examined the expression
of VCAM-1 (an important regulator that promotesmonocyte adhesion
to endothelial cells). Treatment of OASFs with CCN4 (1–30 ng/ml)
for 24 h induced VCAM-1 mRNA and cell surface VCAM-1 expression
in a concentration-dependent manner, as determined by qPCR and
ﬂow cytometry (Fig. 1C and D). In addition, CCN4 also increased
VCAM-1 mRNA and protein expression in a time-dependent manner
(Fig. 1E&F). These data indicate that CCN4 increases VCAM-1 expres-
sion in human OASFs. To determine whether CCN4-induced VCAM-1
expression is dependent on de novo protein synthesis, the cells were
pretreated with actinomycin D or cycloheximide and then incubated
with CCN4. Treatment with actinomycin D or cycloheximide reduced
CCN4-mediated VCAM-1 expression (Fig. 1G), suggesting that CCN4-
induced VCAM-1 expression is mediated via the de novo protein syn-
thesis through transcription and translation.
Integrins are well-known receptors for CCN proteins [22]. There-
fore, we hypothesized that the integrin receptor signaling pathway
may be involved in CCN4-induced VCAM-1 expression, and sought
to identify the integrin receptor subtypes that may be involved in
the CCN4-induced increase in VCAM-1 expression. We found that
αvβ5 and α6β1 integrin receptor-speciﬁc mAbs signiﬁcantly blocked
the CCN4-induced increase in VCAM-1 expression in human OASFs,) OASFs were pretreated for 30 min with GF109203X (3 μM), rottlerin (10 μM), and
for 24 h, and VCAM-1 expression was examined by qPCR, ﬂow cytometry, and Western
th αvβ5 mAb, α6β1 mAb, or Syk inhibitor for 30 min before incubation with CCN4 for
pressed as the mean±S.E. *: pb0.05 as compared with basal level. #: pb0.05 as com-
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control IgG did not have this effect (Fig. 1H–J). A combination of
αvβ5 and α6β1 integrin mAbs completely abolished CCN4-induced
VCAM-1 expression (Fig. 1H). These data suggest that CCN4-induced
VCAM-1 expression may occur via the activation of αvβ5 and α6β1
integrin receptors.
3.2. Syk is involved in the potentiating action of CCN4
Previous studies have demonstrated that integrin-mediated adhe-
sion involves Syk phosphorylation [23,24]. To determine whether Syk
was involved in CCN4-induced VCAM-1 expression, we pretreated
OASFs with a Syk inhibitor (10 μM) for 30 min. The Syk inhibitor
antagonized the potentiating effect of CCN4 (Fig. 2A–C). Next, we
speciﬁcally inhibited Syk expression using an siRNA; the transfection
of OASFs with a Syk siRNA reduced Syk expression and inhibited the
CCN4-induced increase in VCAM-1 production (Fig. 2B and C). To fur-
ther determine whether Syk played a crucial role in CCN4-induced
VCAM-1 production, we directly measured Syk phosphorylation in re-
sponse to CCN4. CCN4 treatment induced Syk phosphorylation in a
time-dependent manner in OASFs (Fig. 2D). In addition, Syk kinase
activity in OASFs was also increased in a time-dependent manner by
CCN4 treatment (Fig. 2E). Furthermore, pretreatment of OASFs for
30 min with αvβ5 and α6β1 integrin mAbs inhibited the CCN4-Fig. 4. JNK is involved in CCN4-induced VCAM-1 expression in synovial ﬁbroblasts. (A–C)
(10 μM), and PD98059 (10 μM) or transfected with JNK mutant for 24 h followed stimulate
and Western blotting. (D) OASFs were incubated with CCN4 for indicated time intervals, an
expressed as the mean±S.E. *: pb0.05 as compared with basal level. #: pb0.05 as compareinduced increase in Syk phosphorylation and kinase activity (Fig. 2F
and G). Based on these results, it appears that CCN4 acts through
αvβ5/α6β1 integrin to enhance VCAM-1 expression in OASFs via Syk
activation.
3.3. PKCδ and JNK signaling pathways are involved in CCN4-induced
VCAM-1 expression
A Syk-dependent PKCδ pathway has been shown to be involved in
TNF-α-induced gene expression in SFs [25]. Therefore, we examined
whether PKCδ was involved in CCN4-induced VCAM-1 expression.
Pretreatment of cells with PKC inhibitor (GF109203X, 3 μM) and
PKCδ inhibitor (rottlerin, 10 μM) but not PKCα inhibitor (Ro320432,
10 μM) reduced CCN4-induced VCAM-1 expression (Fig. 3A–C). Fur-
thermore, transfection of OASFs with a PKCδ siRNA speciﬁcally re-
duced PKCδ expression and inhibited the CCN4-induced increase in
VCAM-1 expression (Fig. 3B and C). We then measured PKCδ phos-
phorylation in response to CCN4. As shown in Fig. 3D, treatment of
OASFs with CCN4 resulted in a time-dependent phosphorylation of
PKCδ. Pretreatment of cells with the αvβ5 and α6β1 mAbs or the Syk
inhibitor blocked the CCN4-induced PKCδ phosphorylation (Fig. 3E).
Taken together, these results indicate that an integrin receptor-, Syk-,
and PKCδ-dependent pathway is involved in CCN4-induced VCAM-1
expression.OASFs were pretreated for 30 min with SP600125 (3 μM), SB203580 (10 μM), U0126
d with CCN4 for 24 h, and VCAM-1 expression was examined by qPCR, ﬂow cytometry,
d ERK, p38, and JNK phosphorylation was determined by Western blotting. Results are
d with CCN4-treated group.
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tions [26]. Therefore, we examined whether CCN4 stimulation en-
hanced MAPK activation in human OASFs. Pretreatment of cells
for 30 min with a JNK inhibitor (SP600125) but not p38 inhibitor
(SB203580) or ERK inhibitor (U0126 and PD98059) reduced CCN4-
induced VCAM-1 expression (Fig. 4A–C). Furthermore, stimulation
of OASFs with CCN4 induced the phosphorylation of JNK, but not
ERK and p38, in a time-dependent manner (Fig. 4D). Based on these
results, it appears that JNK activation is involved in CCN4-mediated
VCAM-1 expression in human OASFs. CCN4 acts through a signaling
pathway involving the αvβ5/α6β1 integrin receptor, Syk, PKCδ, and
JNK to enhance VCAM-1 expression in human OASFs.
3.4. Involvement of AP-1 in CCN4-induced VCAM-1 expression
AP-1 is a transcription factor that plays a crucial role in immune
and inﬂammatory responses. The VCAM-1 promoter contains binding
sites for AP-1 [20,27]. Therefore, we examined the effect of CCN4 on
AP-1 transcriptional activation. Pretreatment of cells for 30 min with
AP-1 inhibitor (curcumin and tanshinone) inhibited CCN4-induced
VCAM-1 expression (Fig. 5A–C). AP-1 activationwas further evaluated
by analyzing the phosphorylation and translocation of c-Jun as well asFig. 5. AP-1 is involved in the potentiation of VCAM-1 expression by CCN4. (A–C) OASFs we
with c-Jun siRNA for 24 h then stimulated with CCN4 for 24 h, and VCAM-1 expression wa
with CCN4 for indicated time intervals, and c-Jun expression in cytosol and nucleus and c-J
mean±S.E. *: pb0.05 as compared with basal level. #: pb0.05 as compared with CCN4-treby chromatin immunoprecipitation assay. Stimulation of cells with
CCN4 increased c-Jun phosphorylation and nuclear translocation
(Fig. 5D).
The in vivo recruitment of c-Jun to the VCAM-1 promoter (−403 to
−30) was assessed using chromatin immunoprecipitation assay [20].
In vivo binding of c-Jun to the AP-1 element of the VCAM-1 promoter
was observed after CCN4 stimulation (Fig. 6A). The CCN4-induced
binding of c-Jun to the AP-1 element was attenuated by Syk inhib-
itor, rottlerin, SP600125, but not Ro320432 (Fig. 6A). In addition,
pretreatment of cells with αvβ5 or α6β1 integrin mAb, Syk inhibitor,
GF109203X, and rottlerin also reduced CCN4-induced c-Jun phos-
phorylation (Fig. 6B). To directly determine whether AP-1 was acti-
vated after CCN4 treatment, OASFs were transiently transfected with
AP-1 luciferase as an indicator of AP-1 activation. As shown in Fig. 6C,
24-h CCN4 treatment increased AP-1-luciferase activity in a dose-
dependent manner. In addition, Syk inhibitor, GF109203X, rottlerin,
curcumin, and tanshinone antagonized the CCN4-induced AP-1 lucifer-
ase activity (Fig. 6C). Co-transfection of cells with Syk and PKCδ siRNAs
or the JNK mutant also reduced CCN4-induced AP-1 luciferase activity
(Fig. 6C). These results indicate that CCN4-induced VCAM-1 expression
is mediated through the αvβ5/α6β1 integrin, Syk, PKCδ, JNK, and AP-1
pathways in human OASFs.re pretreated for 30 min with curcumin (3 μM) and tanshinone (5 μM) or transfected
s examined by qPCR, ﬂow cytometry, and Western blotting. (D) OASFs were incubated
un phosphorylation was determined by Western blotting. Results are expressed as the
ated group.
Fig. 6. CCN4 induced AP-1 activation through integrin/Syk/PKCδ and JNK pathways. (A) OASFs were pretreated with αvβ5 mAb, α6β1 mAb, Syk inhibitor, GF109203X, and rottlerin
for 30 min then stimulated with CCN4 for 120 min, the chromatin immunoprecipitation assay was then performed. (B) OASFs were pretreated with Syk inhibitor, GF109203X,
rottlerin, Ro320432, and SP600125 for 30 min then stimulated with CCN4 for 30 min, and p–c-Jun expression was determined by Western blotting. (C) OASFs were pretreated
with Syk inhibitor, GF109203X, rottlerin, curcumin, and tanshinone for 30 min or transfected with Syk and PKCδ siRNA or JNK mutant before exposure to CCN4. AP-1 luciferase
activity was measured, and the results were normalized to the β-galactosidase activity and expressed as the mean±S.E. for three independent experiments performed in triplicate.
(D&E) OASFs were incubated with various concentrations of CCN4 for 24 h or transfected with VCAM-1 siRNA for 24 h then stimulated with CCN4 for 24 h. THP-1 cells labeled with
BCECF-AM were added to OASFs for 6 h, and then the THP-1 cell adherence was measured by ﬂuorescence microscopy. Results are expressed as the mean±S.E. *: pb0.05 as com-
pared with basal level. #: pb0.05 as compared with CCN4-treated group.
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To further determine the functional signiﬁcance of VCAM-1 ex-
pression in OASFs, we examined monocyte adhesion to these cells
after treatment with CCN4. The adhesion assay was carried out using
THP-1 cells as a monocyte model. CCN4 dose-dependently enhanced
the adhesiveness between OASFs and THP-1 cells (Fig. 6D). We next
examined whether VCAM-1 induced monocytes to adhere to OASF
monolayers. Transfection of OASFs with VCAM-1 siRNA signiﬁcantly
inhibited monocyte adhesion (Fig. 6E). These results indicate that
CCN4 increases VCAM-1 expression in OASFs and promotes the adhe-
sion of monocytes to OASFs.
4. Discussion
OA is a heterogeneous group of conditions associated with defec-
tive integrity of the articular cartilage as well as related changes inthe underlying bone. The chronic inﬂammatory process is mediated
by a complex cytokine network. The factors responsible for initiating
the degradation and loss of articular tissues remain unknown. Al-
though the pathogenesis of the disease remains elusive, upregulation
of adhesion molecules on the surface of the synovial lining may play a
key role in recruitment and inﬁltration of monocytes into sites of in-
ﬂammation in OA [28]. Here, we identiﬁed VCAM-1 as a target protein
for the CCN4 signaling pathway that regulates the cell inﬂammatory
response. We also showed that potentiation of VCAM-1 by CCN4 re-
quires activation of the integrin receptor, Syk, PKCδ, JNK, and AP-1
signaling pathways and promotes monocyte adhesion to OASFs.
CCN4 is known to activate integrin, including α5β1, αvβ3, αvβ5,
and α6β1 [29,30]. However, we demonstrated that αvβ5 and α6β1
integrin but not α5β1 and αvβ3 integrin receptor were required
for CCN4-induced VCAM-1 expression. Treatment cells with αvβ5
and α6β1 integrin mAb inhibited CCN4-induced VCAM-1 expression,
but α5β1 and αvβ3 integrin mAb failed to inhibit CCN4-induced
974 J.-F. Liu et al. / Biochimica et Biophysica Acta 1833 (2013) 966–975VCAM-1 expression. These data suggest that αvβ5 and α6β1 integrin
are involved in CCN4-induced VCAM-1 expression and release from
synovial ﬁbroblasts.
It has been reported that Syk can be activated by integrin adhesion
receptors [31]. In addition, the interaction of integrins with other in-
tracellular proteins such as tyrosine kinase Syk, which binds to the β3
integrin cytoplasmic tail leading to regulate osteoclast function and
the capacity of the mature resorptive cell to resorb bone [22]. We
demonstrated that Syk inhibitor antagonized the CCN4 mediated po-
tentiation of VCAM-1 expression, suggesting that Syk activation is an
obligatory event in CCN4-induced VCAM-1 expression in these cells.
In addition, transfection of OASFs with Syk siRNA reduced CCN4 me-
diated potentiation of VCAM-1 expression from synovial ﬁbroblasts.
These data suggest that the Syk pathway is required for CCN4-induced
VCAM-1 expression.
Several isoforms of PKC have been characterized at the molecular
level and have been found to mediate several cellular molecular
responses [32]. We demonstrated that the PKC inhibitor GF109203X
antagonized the CCN4-mediated potentiation of VCAM-1 expression,
suggesting that PKC activation is an obligatory event in CCN4-
induced VCAM-1 expression in these cells. In addition, rottlerin but
not Ro320432 also inhibited CCN4-induced VCAM-1 expression. How-
ever, current report indicated that rottlerin is not a speciﬁc PKCδ in-
hibitor but inhibits may other targets [33]. Therefore, we used PKCδ
siRNA to conﬁrm PKCδ function in OASFs. We found that PKCδ siRNA
inhibited the enhancement of VCAM-1 expression. Incubation of sy-
novial ﬁbroblasts with CCN4 also increased PKCδ phosphorylation.
On the other hand, αvβ5 and α6β1 mAb or Syk inhibitor blocked the
CCN4-induced PKCδ phosphorylation. These data suggest that the
αvβ5/α6β1 integrin and PKCδ pathways are required for CCN4-induced
VCAM-1 expression.
There are several binding sites for a number of transcription fac-
tors including NF-κB, Sp-1, and AP-1 in the 5′ region of the VCAM-1
gene [34]. Recent studies of the VCAM-1 promoter have demonstrat-
ed that VCAM-1 induction by several transcription factors occurs in a
highly stimulus-speciﬁc or cell-speciﬁc manner [35]. The results
of our current study show that AP-1 activation contributes to CCN4-
induced VCAM-1 expression in synovial ﬁbroblasts. Pretreatment of
cells with an AP-1 inhibitor curcumin or tanshinone reduced CCN4-
increased VCAM-1 expression. Therefore, the AP-1 binding site is
likely to be the most important site for CCN4-induced VCAM-1 pro-
duction. The AP-1 sequence binds to members of the Jun and Fos
families of transcription factors. These nuclear proteins interact with
the AP-1 site as Jun homodimers or Jun-Fos heterodimers formed by
protein dimerization through their leucine zipper motifs [36]. The
results of our study show that CCN4 induced c-Jun phosphorylation.
In addition, c-Jun siRNA abolished CCN4-induced VCAM-1 expression
in OASFs. Therefore, c-Jun activation mediates by CCN4-increased
VCAM-1 expression. Furthermore, CCN4 increased the binding of
c-Jun to the AP-1 element within the VCAM-1 promoter, as shown by
a chromatin immunoprecipitation assay. Binding of c-Jun to the AP-1
element was attenuated by Syk inhibitor, rottlerin, and SP600125.
Using transient transfection with AP-1-luciferase as an indicator of
AP-1 activity, we also found that CCN4 induced an increase in AP-1 ac-
tivity. In addition, Syk inhibitor, GF109203X, rottlerin, curcumin, and
tanshinone reduced CCN4-increased AP-1 promoter activity. These re-
sults indicate that the CCN4 may act through the αvβ5/α6β1 integrin,
Syk, PKCδ, JNK, and AP-1 pathways to induce VCAM-1 production in
human OASFs.
In conclusion, the signaling pathway involved in CCN4-induced
VCAM-1 expression in human SFs was investigated. CCN4 increased
VCAM-1 production by binding to the αvβ5/α6β1 integrin receptor
and activating Syk, PKCδ, and JNK, which enhances AP-1 binding and
transactivation of VCAM-1 expression. The CCN4-induced VCAM-1 ex-
pression promotedmonocyte adhesion to humanOASFs. These ﬁndings
provide a better understanding of the mechanisms of OA pathogenesis.Conﬂict of interest statement
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